Charlottesville, VA (CVILLE RIGHT NOW) – The University of Virginia’s Gynecologic Oncology program continues to make strides in cancer research, ranking fourth nationally for clinical trial enrollment. Dr. Linda Duska, professor of gynecologic oncology and associate dean for clinical research at UVA’s School of Medicine, highlighted the significance of this achievement, stating, “When we have these trials open at sites like the University of Virginia and women participate in the studies, they can get access to these novel drugs that work better than the drugs that we have now, even before they’re FDA approved.”

UVA’s research efforts have led to groundbreaking advancements in gynecologic cancer treatment, particularly in ovarian, endometrial, and cervical cancers. Dr. Duska emphasized the impact of clinical trials in improving patient outcomes, explaining, “Over the past even five years, the advances we’ve made in the standard of care in all of these diseases, women are living longer, they’re feeling better, and all of this is as a result of clinical research.” The program’s success has drawn patients from across Virginia and beyond, giving more women access to cutting-edge therapies.

As a leader in gynecologic oncology research, UVA has contributed to the approval of multiple new cancer treatments, including immunotherapy and antibody drug conjugates. Dr. Duska expressed optimism for the future, noting that research-driven care offers the best possible outcomes for patients. With ongoing studies and continuous advancements, UVA remains at the forefront of innovative cancer treatment, providing hope and improved survival rates for women battling gynecologic cancers.

Listen to the full conversation here: